134682-44-3

Basic information

• Product Name: Ethyl Cyclohexyl-difluoroacetate
• Synonyms: Ethyl Cyclohexyl-difluoroacetate
• CAS NO: 134682-44-3
• Molecular Formula: C₁₀H₁₆F₂O₂
• Molecular Weight: 206.2296464
• Mol File: 134682-44-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl Cyclohexyl-difluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl Cyclohexyl-difluoroacetate(134682-44-3)
• EPA Substance Registry System: Ethyl Cyclohexyl-difluoroacetate(134682-44-3)

Safety Data

• Hazardous Substances Data: 134682-44-3(Hazardous Substances Data)

Upstream product

• 667-27-6 Ethyl bromodifluoroacetate 
• 110-83-8 cyclohexene 
• 13275-31-5 ethyl cyclohexyloxoacetate 
• 108-85-0 1-bromocyclohexane 
• 101068-11-5 ethyl 2,2-difluoro-2-(phenylthio)acetate 
• 698378-63-1 ethyl α,α-difluoro-α-(phenylseleno)acetate 
• 134682-30-7 cis-ethyl-α,α-difluoro-(2-iodocyclohexanyl)acetate 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 

Downstream Products

• 1007578-79-1 2-cyclohexyl-2,2-difluoroacetamide 
• 1007578-80-4 (2-cyclohexyl-2,2-difluoroethyl)amine hydrochloride 

Relevant articles and documents

Selective difluoroalkylation of alkenes by using visible light photoredox catalysis

A visible light-induced process for selective difluoroalkylation of unactivated alkenes has been developed. The choice of base is crucial for governing the chemoselectivity of the process to produce difluoroalkylated alkanes and alkenes. This journal is

Photoredox-Catalyzed Hydrodifluoroalkylation of Alkenes Using Difluorohaloalkyl Compounds and a Hantzsch Ester

Photoredox-catalyzed hydrodifluoroalkylation of alkenes proceeded smoothly in the presence of a Hantzsch ester as a hydrogen source under visible light irradiation. The reaction was also applicable to the hydrodifluoroalkylation of alkynes, and a continuous photo flow reaction was also successful.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.